A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL

Inclusion Criteria: General Inclusion Criteria:

• At least one bi-dimensionally measurable lymphoma lesion on CT scan defined as > 1.5cm in its longest dimension, which is also FDG avid by screening PET scan.

• Confirmed availability of archival or freshly biopsied tumor tissue prior to studyenrollment

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

• Adequate hematologic function

• For female participants of childbearing potential, agreement to use highly effectiveforms of contraception Dose-Escalation Portion of the Study:

• Participants must have histologically confirmed B‑cell NHL, except MCL or SLL

• Participants must have never received previous R-CHOP treatment

• Any relapsed/refractory participants that are enrolled during the dose escalationshould have received only a single previous treatment regimen Expansion Portion of the Study:

• Participants must have previously untreated CD20‑positive DLBCL and IPI score must be 2-5

Exclusion Criteria: General Exclusion Criteria:

• History of severe allergic or anaphylactic reactions to humanized or murine monoclonalantibodies or known sensitivity or allergy to murine products

• Contraindication to receive any of the individual components of CHOP, rituximab orobinutuzumab

• Prior anthracycline therapy

• Participants with ongoing corticosteroid use >30 mg per day of prednisone orequivalent

• CNS lymphoma or primary mediastinal DLBCL

• Vaccination with live vaccines within 28 days prior to randomization

• Chemotherapy or other investigational therapy within 28 days prior to the start ofCycle 1

• History of other malignancy that could affect compliance with the protocol orinterpretation of results

• Evidence of significant, uncontrolled concomitant disease

• Significant cardiovascular disease or significant pulmonary disease

• Left ventricular ejection fraction less than (<) 50% as defined by multiple-gatedacquisition (MUGA)

• Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episodeof infection requiring treatment with IV antibiotics or hospitalization (relating tothe completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1

• Received the following agents within 7 days prior to the first dose of venetoclax:steroid therapy for anti-neoplastic intent; strong and moderate cytochrome P450 (CYP) 3A4 inhibitors or inducers; grapefruit/grapefruit products, seville oranges or starfruit within 3 days prior to the first dose of venetoclax

• Clinically significant history of liver disease, including viral or other hepatitis,current alcohol abuse, or cirrhosis

• Recent major surgery

• Women who are pregnant or lactating Dose-Escalation Portion of the Study:

• Participants with confirmed mantle cell lymphoma (MCL) or small lymphocytic lymphoma (SLL) Expansion Portion of the Study:

• Participants with transformed lymphoma (participants with discordant bone marrowinvolvement (i.e., low grade histology in bone marrow) may be considered afterdiscussion with the Medical Monitor)

• Prior therapy for NHL